Commodore Capital LP Cyclacel Pharmaceuticals, Inc. Transaction History
Commodore Capital LP
- $1.12 Billion
- Q2 2024
About Cyclacel Pharmaceuticals, Inc.
- Ticker CYCC
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 12,539,200
- Market Cap $6.02M
- Description
- Cyclacel Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer and other proliferative diseases. The company's development programs include fadraciclib, a cyclin dependent kinase Inhibitors (CDK) that is in Phase 1/2 clinical trial for the treatment of solid tumors, as well as in combin...